<DOC>
	<DOCNO>NCT01155206</DOCNO>
	<brief_summary>Insulin resistant state characterize hepatic lipoprotein ( VLDL ) particle overproduction . Numerous hormonal nutritional factor know influence hepatic lipoprotein particle production , include insulin free fatty acid ( FFA ) . In contrast liver , intestine traditionally view 'passive ' organ respect lipoprotein production , intestinal lipoprotein particle production determine mainly amount fat ingest absorbed . Glucagon play key role regulation carbohydrate fatty acid metabolism recently show first time regulate hepatic lipoprotein production mouse . Ours first study investigate effect glucagon hepatic intestinal lipoprotein production human .</brief_summary>
	<brief_title>Acute Regulation Intestinal Hepatic Lipoprotein Production Glucagon</brief_title>
	<detailed_description>Potential role glucagon intestinal hepatic lipoprotein production . Although glucagon , main hormone oppose insulin action , know exert profound effect carbohydrate ( stimulation hepatic glucose production ) fatty acid metabolism ( stimulation hepatic b-oxidation ketogenesis ) , potential role regulation lipoprotein metabolism largely overlook mechanism whereby glucagon modulate hepatic lipid metabolism human previously examine . Longuet et al recently show glucagon receptor ( Gcgr ) signal essential control hepatic lipid homeostasis mouse ( 44 ) . They show Gcgr-/- mouse exhibit high plasma TG level increase hepatic TG production compare littermate control . Conversely , glucagon administration wildtype mouse decrease hepatic lipid production plasma TGs . A combination microarray RealTime PCR analyse demonstrated period fast increased expression gene regulate fatty acid b-oxidation +/+ Gcgr-/- mouse . Furthermore , exogenous glucagon administration mimic increase expression enzyme involve b-oxidation fast +/+ mouse . Enzymes involve fatty acid synthesis regulate exogenous glucagon . Gcgr-/- mice much susceptible accumulation lipid liver , know associated development non-alcoholic steatohepatitis . To date , glucagon regulation intestinal lipoprotein production examine animal human . There convince evidence mouse study glucagon play major role regulation hepatic lipoprotein production may also play role intestinal lipoprotein assembly secretion . Ours first study examine role glucagon hepatic intestinal lipoprotein production human . Since inhibition glucagon receptor activity currently explore therapeutic approach treatment Type 2 diabetes , study provide important information regard potential implication therapeutic approach control lipid homeostasis general metabolic health .</detailed_description>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>1 . Men woman , age 18 40 year 2 . Body mass index 20 kg/m2 25 kg/m2 3 . Hemoglobin 130g/L . 4 . Normal glucose tolerance response 75g , 2hr OGTT 1 . Subject history hepatitis/hepatic disease active within previous two year . 2 . Any significant active ( past 12 month ) disease gastrointestinal , pulmonary , neurological , renal ( Cr &gt; 1.5 mg/dL ) , genitourinary , hematological system , severe uncontrolled treated untreated hypertension ( sit diastolic BP &gt; 100 systolic &gt; 180 ) proliferative retinopathy 3 . Fasting blood glucose &gt; 6.0 mmol/l know diabetes . 4 . Any history MI clinically significant , active , cardiovascular history include history arrhythmia 's conduction delay ECG , unstable angina , decompensated heart failure . 5 . Any laboratory value : AST &gt; 2x ULN ; ALT &gt; 2x ULN TSH &gt; 6 mU/l 6 . Current addiction alcohol substance abuse determine investigator . 7 . Mental incapacity , unwillingness language barrier preclude adequate understanding cooperation 8 . Taking prescription nonprescription medication time study 9 . Having donate blood three month prior three month post study procedures 10 . A pregnancy test perform 1 3 day prior study female subject . Those test positive pregnancy exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>glucagon ,</keyword>
	<keyword>high physiological dose basal dose glucagon</keyword>
	<keyword>hepatic lipoprotein production ,</keyword>
	<keyword>free fatty acid</keyword>
	<keyword>intestinal lipoprotein production</keyword>
	<keyword>particle</keyword>
	<keyword>glucagon affect production fat intestine liver .</keyword>
</DOC>